Glenmark Pharmaceuticals Q1 FY27 Results Analysis: Revenue Surges 23%, Zero Gross Debt Achieved

Glenmark Pharmaceuticals Ltd's Q1 FY27 numbers came in strong, with revenue of Rs. 4,018.48 Cr (+23.10% YoY) and PAT growth of +930.34% YoY. Here's a quick read of what worked, what to watch, and what management said.

Quarter Snapshot

Revenue grew 23.1% YoY to a record Q1, EBITDA margin improved 225 bps to 20.03%, but missed the 23% target. Zero gross debt was achieved and Monroe facility restart provides a catalyst, though subsidiary losses remain a drag.

Key Investment Insights

Key Positives

• Revenue of Rs.4,018.48 Cr, highest-ever Q1, grew 23.1% YoY.
• EBITDA margin improved 225 bps YoY to 20.03%.
• PAT of Rs.482.83 Cr (EPS Rs.17.11) on a clean quarter with zero exceptional items.
• Zero gross debt achieved as of FY26, meeting Glenmark 3.0 target.
• Monroe facility cleared VAI status, restarting commercial manufacturing.
• Gross margin stable at ~69% despite API cost inflation.

Risk Factors

• EBITDA margin of 20.03% missed the company's 23% target by ~3pp.
• Subsidiaries were a net drag of Rs.252.81 Cr on consolidated PAT.
• Finance costs rose 26.7% QoQ to Rs.54 Cr, partly due to Nebulizer transaction.
• Cash tax rate of 32.77% is above effective rate of 24.96%, indicating timing differences.